Please assess the completion status of the following clinical trial:

Trial Title: A Study of Belimumab in Subjects With Systemic Lupus Erythematosus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Key Inclusion Criteria:~* Clinical diagnosis of SLE by ACR criteria.~* Active SLE disease.~* Autoantibody-positive.~* On stable SLE treatment regimen.~Key Exclusion Criteria:~* Pregnant or nursing~* Have received treatment with any B cell targeted therapy.~* Have received treatment with a biological investigational agent in the past year.~* Have received IV cyclophosphamide within 180 days of Day 0.~* Have severe lupus kidney disease.~* Have active central nervous system (CNS) lupus.~* Have required management of acute or chronic infections within the past 60 days.~* Have current drug or alcohol abuse or dependence.~* Have a historically positive test or test positive at screening for HIV, hepatitis B, or hepatitis C.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo
- Belimumab 1 mg/kg (Type: EXPERIMENTAL): Belimumab 1 mg/kg
- Belimumab 10 mg/kg (Type: EXPERIMENTAL): Belimumab 10 mg/kg

Based on this trial design, predict the completion outcome and termination type (if applicable).